China CMO

China’s Zhixiang – A Global Pharmaceutical Industry

In 1978, if anyone had been told that within 40 years Maoist-oriented China would be rapidly gaining on the United States as having the largest economy in the world, you would have been labelled delusional, if not totally…


China’s Regulatory Mosaic: The Troops Have Their Marching Orders

China’s State Council has announced to its people and to the world that the second largest drug market will become a world leader in pharmaceutical innovation, commercialization and manufacturing. Simply put, China will no longer rely on research-based…


China’s Drug Industry Reforms: Is the Mosaic Finally Coming Together for Western Pharma?

A note from author David Deere: To foster a global and innovative pharmaceutical industry and reduce the disproportional healthcare costs attributable to drugs, the Chinese government has formally targeted the industry for economic development. To facilitate these objectives,…


Chinese Drug Reform and the Knights Templar: Symbolism or Coincidence?

A David Deere Advisory Alert Nine centuries ago, wealthy Christians often made pilgrimages from Europe to Jerusalem, among the most sacred places in the Holy Land. It was, to say the least, an arduous and dangerous journey. In…


The Year of the Fire Rooster Sets the Stage for China-US Relations

“Always higher, always going on.” – Motto of the Chinese Zodiac’s Rooster It seems appropriate that China’s 2017 New Year is the year of the Red Fire Rooster. The tenth Chinese zodiac sign, the Rooster is known for…


Update on CFDA’s Fast-Track Approval: 7 MNC Products Move to Data Inspection Stage

It’s been a little more than a year since China’s FDA (CFDA) announced sweeping policy changes intended to streamline the review of innovative new drugs and rid their system of subpar applicants blocking the progress of true candidates…


PaizaBio’s Message for J.P. Morgan Week? China Is Open for Business

ALBUQUERQUE, New Mexico (January 5, 2017) – As thousands of life sciences executives and investors descend on San Francisco for the 35th Annual J.P. Morgan Healthcare Conference next week, PaizaBio has a simple message: China, the world’s second…


China’s Pharmaceutical “Sea Turtles” – Innovation or Imitation and Does It Matter?

During a discussion about the future direction of immuno-oncology pharmaceuticals at the Annual ChinaBio® Partnering Meeting held in Suzhou, China, last May, one point of disagreement among the panelists was whether the number of Chinese companies targeting development…


PaizaBio’s Deere to Reveal Global Pharma’s Salvation at CPhI Pharma Insights

“China is in the midst of regulatory ‘shock and awe.’ PaizaBio provides multinational pharmaceutical companies with much needed on-the-ground insight and a clear path forward in China.” October 4, 2016 I 2:30 PM I Pharma Forum Theater 1,…